Trials / Terminated
TerminatedNCT01696045
Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma
Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage IV Malignant Melanoma
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 14 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 12 Years – 17 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to comply with the Pediatric Investigation Plan requirements of Ipilimumab
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Ipilimumab |
Timeline
- Start date
- 2012-11-12
- Primary completion
- 2016-07-31
- Completion
- 2016-07-31
- First posted
- 2012-09-28
- Last updated
- 2017-08-29
- Results posted
- 2017-08-01
Locations
32 sites across 8 countries: United States, Belgium, Denmark, France, Germany, Mexico, Spain, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT01696045. Inclusion in this directory is not an endorsement.